Zobrazeno 1 - 10
of 127
pro vyhledávání: '"Hiroshi Ureshino"'
Autor:
Hiroshi Ureshino, Kazuharu Kamachi, Haruhiko Sano, Sho Okamoto, Hidekazu Itamura, Mariko Yoshimura, Hiroo Katsuya, Toshihiko Ando, Shinya Kimura
Publikováno v:
Hematology, Vol 27, Iss 1, Pp 1171-1175 (2022)
Objective Treatment-free remission (TFR) after tyrosine kinase inhibitor (TKI) discontinuation at the first attempt is a therapeutic goal for patients with chronic phase chronic myeloid leukemia (CML-CP). However, it remains unclear whether discontin
Externí odkaz:
https://doaj.org/article/6cf6b52c540c47b884559234884191d8
Autor:
Kazuharu Kamachi, Hiroshi Ureshino, Kazunori Kawasoe, Keisuke Kidoguchi, Yuta Yamamoto, Yuki Fukuda-Kurahashi, Yuki Kurahashi, Tatsuro Watanabe, Shinya Kimura
Publikováno v:
HemaSphere, Vol 7, p e73633b7 (2023)
Externí odkaz:
https://doaj.org/article/245fd5d5e36b4aa891d536a413cead01
Autor:
Hiroshi Ureshino, Yasunori Ueda, Shin Fujisawa, Kensuke Usuki, Hideo Tanaka, Masaya Okada, Shugo Kowata, Kazunori Murai, Asao Hirose, Motohiro Shindo, Takashi Kumagai, Takafumi Nakao, Tomoharu Takeoka, Kazuharu Kamachi, Keisuke Kidoguchi, Satoshi Iyama, Junki Inamura, Tsutomu Kobayashi, Eri Kawata, Hiroshi Ohkawara, Takayuki Ikezoe, Shinya Kimura
Publikováno v:
HemaSphere, Vol 7, p e9072115 (2023)
Externí odkaz:
https://doaj.org/article/5d46986c1a534c98a9f192f73aea65a5
Autor:
Yuta Yamamoto, Tatsuro Watanabe, Hiroshi Ureshino, Kazuharu Kamachi, Yuki Kurahashi, Satoshi Yamashita, Naoko Hattori, Toshikazu Ushijima, Shinya Kimura
Publikováno v:
HemaSphere, Vol 7, p e50279db (2023)
Externí odkaz:
https://doaj.org/article/c9d7d59fc15f49e7bc2224044072e114
P1236: REGULATION OF DNA AND HISTONE METHYLATION THROUGH METHIONINE METABOLISM IN ATL LEUKEMOGENESIS
Autor:
Tatsuro Watanabe, Sho Kitamura, Keita Kai, Satoshi Yamashita, Naoko Hattori, Yuta Yamamoto, Kazuharu Kamachi, Yuki Kurahashi, Hiroshi Ureshino, Yuki Fukuda-Kurahashi, Hideaki Nakamura, Akemi Sato, Seiji Okada, Toshikazu Ushijima, Eisaburo Sueoka, Shinya Kimura
Publikováno v:
HemaSphere, Vol 7, p e325001a (2023)
Externí odkaz:
https://doaj.org/article/91797acf688c49edba454650ee2f0b18
Autor:
Taro Edahiro, Hiroshi Ureshino, Ren Chishaki, Keita Fujino, Tatsuji Mino, Tetsumi Yoshida, Noriyasu Fukushima, Tatsuo Ichinohe
Publikováno v:
eJHaem, Vol 4, Iss 1, Pp 273-275 (2023)
Abstract Translocation t(6;11) occurs in approximately 5% of patients with acute myeloid leukemia (AML) corresponding to 11q23/mixed lineage leukemia (MLL) rearrangement. The AF6 gene on chromosome 6q27 is the fusion partner of the MLL gene on 11q23
Externí odkaz:
https://doaj.org/article/e94876733feb4e538b5ba49a299f6e09
Autor:
Hiromi Nishi, Susumu Horikoshi, Kouji Ohta, Tetsumi Yoshida, Noriyasu Fukushima, Kyoko Oshita, Syuichi Munenaga, Taro Edahiro, Hiroshi Ureshino, Hideo Shigeishi, Yukio Yoshioka, Masaru Konishi, Noriaki Ide, Yuma Ogawa, Rikou Marukawa, Tomoaki Shintani, Natumi Ino, Mikihito Kajiya, Naoya Kakimoto, Hiroki Ohge, Tatsuo Ichinohe, Hiroyuki Kawaguchi
Publikováno v:
Journal of Personalized Medicine, Vol 13, Iss 11, p 1603 (2023)
Oral mucositis significantly affects the quality of life in hematologic cancer patients undergoing hematopoietic stem cell transplantation. Despite global evidence supporting the efficacy of low-level laser therapy (LLLT) for mucositis prevention, it
Externí odkaz:
https://doaj.org/article/6d98765415d14a628c0b8c97c775821e
Autor:
Kazunori Kawasoe, Tatsuro Watanabe, Nao Yoshida-Sakai, Yuta Yamamoto, Yuki Kurahashi, Keisuke Kidoguchi, Hiroshi Ureshino, Kazuharu Kamachi, Yuki Fukuda-Kurahashi, Shinya Kimura
Publikováno v:
Cancers, Vol 15, Iss 20, p 5089 (2023)
The recent evolution of molecular targeted therapy has improved clinical outcomes in several human malignancies. The translocation of anaplastic lymphoma kinase (ALK) was originally identified in anaplastic large-cell lymphoma (ALCL) and subsequently
Externí odkaz:
https://doaj.org/article/fe0336886cee41889564a69c906fa0a4
Publikováno v:
Immunological Medicine, Vol 44, Iss 2, Pp 61-68 (2021)
The development of BCR-ABL1 tyrosine kinase inhibitors (TKIs) markedly improved the prognosis of patients with chronic myeloid leukemia (CML). Approximately 50% of patients who achieve deep molecular response (DMR) remain in treatment-free remission
Externí odkaz:
https://doaj.org/article/c215c1291ff845a2a356c0a1d0b79248
Publikováno v:
eJHaem, Vol 3, Iss 3, Pp 1062-1063 (2022)
Externí odkaz:
https://doaj.org/article/4f778386cbda4a3b97a2187e0df63162